Introduction:

Sodium-glucose co-transporter inhibitors´ drugs (SGLT) work by selectively and reversiblely inhibiting at the renal level. Through this mechanism, they reduce glucose reabsorption, which is excreted through urine and thus contribute to normalizing blood glucose.

Objective:

Describe the role of sodium-glucose co-transporter inhibitors 2 in the treatment of diabetes mellitus.

Methods:

There were used as search engines for scientific information : Google Scholar, Google, Pubmed and SciELO. The keywords used were: Glyphozines, sodium-glucose co-transporter inhibitors, diabetes mellitus, treatment and weight loss. Review articles, research articles and web pages were assessed, which generally had less than 10 years of publication, and were in Spanish, Portuguese or English language. Items that did not meet these requirements were excluded. This allowed the study of 98 articles, of which 75 were referenced.

Conclusions:

Administration of sodium-glucose co-transporter inhibitors induces favorable changes in glycosylated haemoglobin, body weight and blood pressure, as well as a low risk of hypoglycaemia. Although they are a pharmacological group that can be used as monotherapy, they are mostly used as adjuvants in the treatment of patients with diabetes mellitus who receive drug treatment with other normo or hypoglycemic medications and who have not met control goals. It is important to be alert to possible side effects or adverse reactions to discontinue treatment and take appropriate action.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )